Engaging with Bispecific T-Cell Engagers
Last Updated: May 16, 2025
An overview of how these agents’ function, their dosing schedules, notable side effects, and the Risk Evaluation and Mitigation Strategies (REMS) requirements for certain agents.
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Up Close with Linvoseltamab
Last Updated: 08/31/2025
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 08/31/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 08/31/2025
Example SOPs and Documents: Bispecific T-Cell Engager Ordering and REMS Compliance
Last Updated: 08/31/2025
PQI
PQI Podcast
Treatment Support Kit
PQI
PQI: Talectrectinib (Ibtrozi) for the Management of ROS1+ Advanced NSCLC
Author: Stefanie Houseknecht, PharmD, BCOP
Last Updated: 08/31/2025
S9 E1: Head & Neck Cancer Care: Clinical Progress & Compassionate Practice
Author: Ginger Blackmon, PharmD | Deborah Wong, MD, PhD
Last Updated: 08/31/2025
Treatment Support Kit: Elranatamab
Last Updated: 08/31/2025
PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer
Author: Shelbie Gibbs, PharmD, BCOP
Last Updated: 08/31/2025